As filed with the Securities and Exchange Commission on February 24, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
KYMERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 81-2992166 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
200 Arsenal Yards Blvd., Suite 230 Watertown, MA | 02472 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan
Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan
(Full title of the plan)
Nello Mainolfi, Ph.D.
Founder, President and Chief Executive Officer
Kymera Therapeutics, Inc.
200 Arsenal Yards Blvd., Suite 230
Watertown, MA 02472
(Name and address of agent for service)
617-300-8460
(Telephone number, including area code, of agent for service)
Copies to:
William D. Collins, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
| Emerging growth company | ☐ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers 2,062,956 additional shares of Common Stock under the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the “Plan”) and 438,898 additional shares of Common Stock under the Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan (the “ESPP”). The number of shares of Common Stock reserved and available for issuance under the Plan is subject to an automatic annual increase on each January 1, beginning in 2021, by an amount equal to the lesser of: (i) four percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or (ii) such number of shares of Common Stock as determined by the compensation committee of the Company’s board of directors. Accordingly, on January 1, 2022, the number of shares of Common Stock reserved and available for issuance under the Plan increased by 2,062,956. The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1, beginning in 2021, by an amount equal to the least of: (i) one percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, (ii) 438,898 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in the ESPP). Accordingly, on January 1, 2022, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 438,898. The additional shares are of the same class as other securities relating to the Plan and the ESPP for which the Registrant’s registration statements filed on Form S-8 filed with the Securities and Exchange Commission on August 21, 2020 (File No. 333-248249) and March 11, 2021 (File No. 333-254122), are effective. The information contained in the Registrant’s registration statements on Form S-8 (Registration Nos. 333-248249 and 333-254122) are hereby incorporated by reference pursuant to General Instruction E.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
| * | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on February 24, 2022.
| KYMERA THERAPEUTICS, INC. | ||||
| By: | /s/ Nello Mainolfi | |||
| Name: | Nello Mainolfi, Ph.D. | |||
| Title: | Founder, President and Chief Executive Officer | |||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Nello Mainolfi, Ph.D. and Bruce Jacobs, CFA, MBA as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for such person in such person’s name, place and stead, in any and all capacities, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 of Kymera Therapeutics, Inc., and any or all amendments (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Nello Mainolfi | Director, Founder, President and Chief Executive Officer (Principal Executive Officer) | February 24, 2022 | ||
| Nello Mainolfi, Ph.D. | ||||
/s/ Bruce Jacobs | Chief Financial Officer | February 24, 2022 | ||
| Bruce Jacobs, CFA, MBA | (Principal Financial Officer) (Principal Accounting Officer) | |||
/s/ Jeffrey Albers | Director | February 24, 2022 | ||
| Jeffrey Albers, J.D., MBA | ||||
/s/ Bruce Booth | Director | February 24, 2022 | ||
| Bruce Booth, D.Phil. | ||||
/s/ Pamela Esposito | Director | February 24, 2022 | ||
| Pamela Esposito, Ph.D. | ||||
/s/ Steven Hall | Director | February 24, 2022 | ||
| Steven Hall, Ph.D. | ||||
/s/ Joanna Horobin | Director | February 24, 2022 | ||
| Joanna Horobin, M.B., Ch.B. | ||||
/s/ Gorjan Hrustanovic | Director | February 24, 2022 | ||
| Gorjan Hrustanovic, Ph.D. | ||||
/s/ John Maraganore | Director | February 24, 2022 | ||
| John Maraganore, Ph.D. | ||||
/s/ Donald W. Nicholson | Director | February 24, 2022 | ||
| Donald W. Nicholson, Ph.D. | ||||
/s/ Elena Ridloff | Director | February 24, 2022 | ||
| Elena Ridloff, CFA | ||||
